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ABSTRACT Vancomycin (VAN) and daptomycin (DAP) are approved as a monotherapy
for methicillin-resistant Staphylococcus aureus (MRSA) bacteremia. A regimen of daptomycin plus ceftaroline (DAP⫹CPT) has shown promise in published case series of MRSA
salvage therapy, but no comparative data exist to compare up-front DAP⫹CPT head-tohead therapy versus standard monotherapy as an initial treatment. In a pilot study, we
evaluated 40 adult patients who were randomized to receive 6 to 8 mg/kg of body
weight per day of DAP and 600 mg intravenous (i.v.) CPT every 8 h (q8h) (n ⫽ 17) or
standard monotherapy (n ⫽ 23) with vancomycin (VAN; dosed to achieve serum trough
concentrations of 15 to 20 mg/liter; n ⫽ 21) or 6 to 8 mg/kg/day DAP (n ⫽ 2). Serum
drawn on the ﬁrst day of bacteremia was sent to a reference laboratory post hoc for
measurement of interleukin-10 (IL-10) concentrations and correlation to in-hospital mortality. Sources of bacteremia, median Pitt bacteremia scores, Charlson comorbidity indices, and median IL-10 serum concentrations were similar in both groups. Although the
study was initially designed to examine bacteremia duration, we observed an unanticipated in-hospital mortality difference of 0% (0/17) for combination therapy and 26%
(6/23) for monotherapy (P ⫽ 0.029), causing us to halt the study. Among patients with an IL-10 concentration of ⬎5 pg/ml, 0% (0/14) died in the DAP⫹CPT
group versus 26% (5/19) in the monotherapy group (P ⫽ 0.057). Here, we share
the full results of this preliminary (but aborted) assessment of early DAP⫹CPT
therapy versus standard monotherapy in MRSA bacteremia, hoping to encourage
a more deﬁnitive clinical trial of its potential beneﬁts against this leading cause
of infection-associated mortality. (The clinical study discussed in this paper has
been registered at ClinicalTrials.gov under identiﬁer NCT02660346.)
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M

ethicillin-resistant Staphylococcus aureus (MRSA) bacteremia is associated with a
signiﬁcant disease burden and a high case fataility, ranging from 20% to 30%,
which is double that seen in methicillin-susceptible S. aureus (MSSA) bacteremia (1–3).
This and other metrics of poor outcomes in patients with MRSA bacteremia are attributed
to inferior pharmacotherapeutic properties of vancomycin (VAN), the cornerstone of MRSA
therapy, compared with ␤-lactam antibiotics used to treat MSSA bacteremia (4, 5). Clinical
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studies demonstrating such differences have been bolstered by experimental data showing
that ␤-lactams not only exert direct antibacterial effects on S. aureus but also synergize with
cationic antimicrobial peptides and other arms of the innate immune system to promote
pathogen clearance (6). These secondary effects may be noteworthy enough that the
addition of antistaphylococcal ␤-lactams (oxacillin, nafcillin, and ﬂucloxacillin) to cornerstone daptomycin (DAP) and VAN can aid in the clearance of refractory MRSA bacteremia,
despite the ␤-lactam agents having no direct anti-MRSA activity, as measured by standard
susceptibility testing methods (7, 8).
Based on a study showing noninferiority of DAP to VAN in treating MRSA bacteremia
(9), the Infectious Diseases Society of America (IDSA) 2011 MRSA treatment guidelines
recommend initiating one of these two agents as ﬁrst-line MRSA bacteremia therapy
(10). Although deﬁnitions vary, initial treatment failure is encountered in up to 50% of
cases and is linked to poor outcomes, including a greater likelihood of metastatic
infections and increased mortality (11–13). The IDSA guidelines recommend switching
to an alternative regimen for persistent MRSA bacteremia of ⱖ7 days or earlier if clinical
deterioration is evident (10). Case reports and series have documented high success in
the treatment of persistent MRSA bacteremia by combining DAP with antistaphylococcal ␤-lactams or ceftaroline (CPT) (14). Potential mechanisms underlying this advantageous dual therapy are (i) ␤-lactam reduction of cell wall cross-linking, enhancing DAP
access to the cell membrane (14); (ii) synergy of ␤-lactams with endogenous cationic
host defense peptides against MRSA (6); and (iii) increased NLRP3 inﬂammasome
activation and interleukin-1␤ (IL-1␤)-mediated bacterial clearance induced by altered
peptidoglycan synthesized by MRSA under ␤-lactam challenge (15, 16). Despite excellent clinical responses to DAP⫹CPT as salvage therapy in difﬁcult MRSA bacteremia
cases, immediate initiation of DAP⫹CPT has not been compared with the current
standard of care monotherapy. Furthermore, data are emerging that suggest that VAN
monotherapy may be insufﬁcient to treat severe MRSA respiratory infections, whereby
a second agent may be needed to the improve outcome (17).
We prospectively examined DAP⫹CPT within 72 h of bacteremia onset to standard
of care VAN or DAP monotherapy in the treatment of MRSA bacteremia in 3 hospital
centers. Due to the fact that the study was not carried out in a blind manner and
because an unexpected mortality difference was identiﬁed before completion, the
study was halted early and the cohort of patients remained small. Serum concentrations of interleukin-10, a strong predictor of mortality in S. aureus bacteremia (15, 18,
19), were evaluated in a blind manner by a reference laboratory post hoc to identify a
high-risk patient subset for whom the clinical beneﬁt of early DAP⫹CPT therapy may
be most pronounced. We present these potentially “hypothesis generating” data to
encourage a larger prospective, randomized, blind clinical trial of combination antimicrobial therapy in the treatment of MRSA bacteremia.
RESULTS
Baseline characteristics. Forty patients over 18 months at 3 hospitals (see Fig. S1
in the supplemental material) were prospectively assigned at random to receive
DAP⫹CPT (n ⫽ 17) or monotherapy with VAN (n ⫽ 21) or DAP (n ⫽ 2). Their baseline
clinical characteristics and comorbidities are shown in Table 1. The groups did not differ
signiﬁcantly in terms of distribution of age, sex, comorbidities, overall comorbid status,
or severity of illness, although trends for some speciﬁc comorbidities were weighted in
one group versus the other. For example, 18% of the combination group had a history
of stroke versus 0% in the monotherapy group (P ⫽ 0.07). Liver disease was also more
prevalent in the combination group (29% versus 9%, P ⫽ 0.11). Chronic lung disease
trended more in the monotherapy group over the combination group (52% versus 24%,
P ⫽ 0.10). Cancer was also weighted more in the monotherapy group (22% versus 0%,
P ⫽ 0.06). The median Pitt bacteremia score was 1 for both groups. The age-adjusted
median Charlson comorbidity index was 5.0 in the combination group and 6.0 in the
monotherapy group (P ⫽ 0.52); 12% (2/17) of the combination therapy patients and
May 2019 Volume 63 Issue 5 e02483-18
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TABLE 1 Patient demographics and characteristicsa
Values by treatment:
Daptomycin plus
ceftaroline (n ⴝ 17)
9 (53)
62
30.7

Vancomycin (n ⴝ 21) or
daptomycin (n ⴝ 2)
16 (70)
62
26.7

Comorbidities, n (%)
Cardiovascular Dz
Diabetes mellitus
Cerebrovascular Dz
End-stage renal Dz
Immunocompromised
Chronic lung Dz
Severe liver Dz
Malignancy
Neutropenia

9
6
3
3
0
4
5
0
0

10 (43)
11 (48)
0 (0)
6 (26)
1 (4)
12 (52)
2 (9)
5 (22)
1 (4)

Charlson index
Mean
Median

4.7
5

5.5
6

Pitt bacteremia score
Mean
Median
Acute renal failure, n (%)
Intensive care, n (%)

1.47
1
3 (18)
3 (18)

1.09
1
5 (22)
3 (13)

aP

(53)
(35)
(18)
(18)
(0)
(24)
(29)
(0)
(0)
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Characteristicb
Male, n (%)
Mean age (yr)
Mean BMI

values are ⬎0.05 for all comparisons.
body mass index; Dz, disease.

bBMI,

13% (3/23) of the monotherapy patients were admitted to the intensive care unit at the
time of infection.
Bacteremia sources. The primary sources of bacteremia (endovascular noncatheter
versus extravascular versus catheter) were evenly distributed among the treatment
groups (Table 2). Foci of infection (more than one may be present per patient) are also
shown in Table 2. Overall, infections were evenly distributed among the groups, except
for a trend toward more vascular catheter infections in the monotherapy group
compared with the combination therapy group (13% versus 0%, P ⫽ 0.12). Most
infections (37/40) were identiﬁed ⱕ72 h within admission.

TABLE 2 Sites of infectiona
Values by treatment, n (%):
Sourceb
1° Bacteremia source
Endovascular
Secondary tissue
Catheter
Foci of infection present
Venous catheter
Urinary tract
Respiratory tract
Surgical wound
Skin/soft tissue
Bone/joint
LVAD
Intra-abdominal
Endocarditis plus TEE
aAll

Daptomycin plus
ceftaroline (n ⴝ 17)

Vancomycin (n ⴝ 21) or
daptomycin (n ⴝ 2)

8 (47)
9 (53)
0 (0)

8 (35)
12 (52)
3 (13)

1
3
1
0
9
5
1
0
3

3
4
6
2
8
4
1
2
1

(6)
(18)
(6)
(0)
(53)
(29)
(6)
(0)
(18)

(13)
(17)
(26)
(9)
(35)
(17)
(4)
(9)
(4)

values are n (%). P values are ⬎0.05 for all comparisons.
destination left ventricular assist device; TEE, transesophageal echocardiogram.

bLVAD,
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TABLE 3 Relevant laboratory and treatment dataa
Values by treatment type:
Metricb
Vancomycin MIC (mg/liter), n (%)
0.5
1
2

Monotherapy

5 (29)
12 (71)
0 (0)

3 (9)
20 (91)
0 (0)

Blood analyses, median (IQR)
WBC (⫻1,000/mm3)
Platelet (⫻1,000/mm3)
CrCl (ml/min)
Procalcitonin (ng/ml)
CRP (mg/liter)
IL-10 (pg/ml)

17.3 (13.7, 22.6)
246 (144, 384)
74 (24, 119)
0.22 (0.07, 0.74)
127 (109, 212)
9.5 (5, 20.5)

14.2 (9.7, 18.5)
173 (98, 323)
47 (16, 114)
0.72 (0.52, 8.8)
176 (108, 236)
7 (5.5, 20.5)

Treatment
Vancomycin trough (initial, mg/liter)
Daptomycin dose (median, mg/kg)

N/Ac
8.6

16.2 (10.7, 19.8)
8.0
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Combination therapy

values are ⬎0.05 for all comparisons.
interquartile range; WBC, white blood cell; CRP, C-reactive protein.
cValues were obtained for only 3 patients prior to randomization with initial trough values (mg/liter), namely,
27, 19, and 9. N/A, not available.
aP

bIQR,

Laboratory data. Relevant laboratory data in the two patient groups are shown in
Table 3. There were no differences in leukocyte count, platelet counts, calculated
creatinine clearance, and C-reactive protein between the groups. Median admission
interleukin-10 (IL-10) concentrations were 9.5 pg/ml and 7 pg/ml for the combination
therapy and monotherapy groups, respectively. All MRSA isolates where combination
therapy was used had CPT and DAP MICs of ⱕ0.5 mg/liter and a VAN MIC of ⱕ1
mg/liter according to the clinical microbiology laboratory.
Treatments. The 23 standard of care patients received a median duration of randomization therapy of 12 days and a total duration of therapy of 26 days. The combination
therapy arm received DAP⫹CPT for a median of 8 days and a mean of 11 days and a total
median treatment duration of 38 days (Fig. S1). The median time to randomization from
onset of bacteremia to initiation of study therapy was 2 days.
Outcomes. Relevant outcomes are listed in Table 4. The median bacteremia duration was 3 days for each group. In-hospital mortality was 0% (0/17) for combination
therapy and 26% (6/23) for monotherapy (P ⫽ 0.029). Among patients with an admission IL-10 concentration of ⱕ5 pg/ml, in-hospital mortality was 0% (0/3) for the
combination group and 25% (1/4) in the monotherapy group (P ⫽ 1.0). For an IL-10
concentration of ⬎5 pg/ml, in-hospital mortality was 0% (0/14) in the combination
therapy group versus 26% (5/19) in the monotherapy group (P ⫽ 0.057).
Notably, but perhaps not surprisingly, mortality lay entirely within the patient cohort
with endovascular sources of primary infection. A subanalysis of this subgroup (called
for by expert reviewers) is shown in Table S1 in the supplemental material and detailed
clinical descriptions in Table S2 in the supplemental material. Most of these cases were

TABLE 4 Study outcomes
Values by treatment type:
Outcome
Mortality, n (%)
In hospital
30 day
90 day

Combination therapy

Monotherapy

P value

0 (0)
0 (0)
0 (0)

6 (26)
6 (26)
7 (30)

0.02
0.02
0.03

Bacteremia duration, median (IQR) days
Length of stay, median (IQR) days

3 (1.5, 5.5)
11 (6, 14)

3 (1, 5.3)
12 (8, 23)

0.56
0.24

May 2019 Volume 63 Issue 5 e02483-18

aac.asm.org 4

Daptomycin plus Ceftaroline in MRSA Bacteremia

Antimicrobial Agents and Chemotherapy

100
Combination therapy

90
80

Survival (%)

70
Standard therapy

60
50

P=0.028
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0

Days
FIG 1 Survival analysis of patients receiving daptomycin plus ceftaroline compared with those receiving
standard of care in a prospective randomized study. Day 0 represents the day of ﬁrst positive blood
culture. Signiﬁcance of mortality difference at 30 days (P ⫽ 0.048) and 60 days (P ⫽ 0.028).

of left-sided endocarditis cases, including those with prosthetic valves and intracardiac
devices, such as left-ventricular assist devices (LVADs) and intracardiac deﬁbrillators
(ICDs). A Kaplan-Meir 60-day survival analysis of the two treatment groups overall is
shown in Fig. 1, demonstrating a signiﬁcantly increased risk of mortality in the standard
of care group compared with the combination therapy group.
Treatment-related adverse events. A summary of adverse events is provided in
Table 5. Three patients that received monotherapy treatment were salvaged with
combination therapy due to treatment failure after 5 days. Of these three, one patient
survived, a second died in the hospital, and the third died from pneumonia due to
extended-spectrum ␤-lactamase (ESBL)-producing Escherichia coli during a follow-up
admission occurring 2 months after the initial presentation. One patient with VAN
therapy developed acute renal failure attributable to VAN. One DAP monotherapy
patient developed asymptomatic elevation in creatinine phosphokinase (CPK) 13 days
into therapy, prompting DAP discontinuation and completion of therapy with 2 additional weeks of CPT. One combination patient was de-escalated to DAP monotherapy
upon discharge from the hospital but developed eosinophilic pneumonia. Therapy was
changed to CPT monotherapy, which was administered for an additional 4 weeks.
Another combination therapy patient was de-escalated at 4 weeks to CPT monotherapy, with a plan to complete 2 more weeks. However, the patient developed
worsening mitral regurgitation, increasing C-reactive protein (CRP) and concern for
pneumonia 5 days after this de-escalation, prompting a switch to telavancin. After a
week of telavancin, an increase in creatinine prompted another switch to linezolid,
which was administered for 1 more week until CRP normalization.
DISCUSSION
Since its emergence as a common nosocomial pathogen in the 1990s, MRSA mortality
and duration of bacteremia were noted to be almost twice that experienced with MSSA
TABLE 5 Treatment-related adverse events
No. of patients
Event
Treatment failure
Acute kidney injury
Asymptomatic elevated CPKc
Eosinophilic pneumonia

Combination therapy
1a
0
0
1d

Monotherapy
3b
1
1
0

aOccurred

after de-escalation to ceftaroline monotherapy.
failure prompting switch to combination therapy at day 5 of therapy.
cCPK, creatine phosphokinase.
dOccurred after de-escalation to daptomycin monotherapy.
bEarly
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infections (4). While the reasons for this disparity were not initially clear, recent insights
about the pharmacodynamic synergy of ␤-lactams with the innate immune system suggested that the absence of such effects among non-␤-lactam drug repertoire available for
MRSA treatment may be responsible (6). The consistent inferior performance of VAN
compared with ␤-lactams in MSSA bacteremia (5, 20–23), coupled with the negative clinical
prognosis conferred upon patients with ␤-lactam drug allergies who are denied ␤-lactam
treatment (24–27), appeared to reinforce this conclusion.
Clinical success has been reported when using DAP⫹CPT as a salvage therapy in
treating refractory MRSA bacteremia (14). This pilot study was performed to compare
the current standard of care for MRSA bacteremia (VAN or DAP monotherapy) with
DAP⫹CPT. Higher mortality was seen in patients with endovascular infections and in
patients with serum IL-10 concentrations of ⬎5 pg/ml who were treated with monotherapy compared with DAP⫹CPT.
The median duration of bacteremia was similar in both groups. A review of these
cases, as well as the data from the CAMERA-1 study (8), demonstrated the presence of
outlier cases of increased duration that may not be captured in median calculations. In
the CAMERA-1 study, outliers with prolonged bacteremia of ⬎4 days were noted in 13
of 49 (27%) VAN monotherapy patients versus only 3 of 46 (7%) in the VAN plus
ﬂucloxacillin group, a difference that is statistically signiﬁcant (P ⫽ 0.01, Fisher’s exact).
Therefore, eliminating or reducing the high-risk outlier patients with prolonged MRSA
bacteremia represents a great medical need of antimicrobial pharmacotherapy that
may be met with the addition of ␤-lactam combination therapy. In this small study, 3
of 23 patients in the monotherapy arm (13%) were salvaged by combination therapy
due to bacteremia duration of ⱖ5 days.
While the DAP⫹CPT combination therapy was very well tolerated overall in this
small cohort, one of its most signiﬁcant limitations is drug cost. The drug acquisition
costs of DAP⫹CPT at the doses employed in this study are about $760/day, a cost at
least 10-times that of VAN (28). However, it is important to highlight that only a fraction
of the treatment duration in the combination therapy group (median, 8 days; mean, 11
days) was with the combination regimen. De-escalation was almost universally adopted
(including 3 patients de-escalated to oral oxazolidinone therapy), in large part because
disposition would have been very difﬁcult on this cumbersome and expensive regimen.
Therefore, an up-front cost of about 10 days of combination therapy, followed by
de-escalation (e.g., VAN) may be more economical than an up-front treatment failure on
monotherapy that requires salvage by a more expensive antimicrobial combination
regimen. Nevertheless, the most cost-effective antimicrobial regimen may well lie in a
more “intermediate” ground, such as VAN plus CPT or DAP plus an antistaphylococcal
␤-lactam or cefazolin. Note that while DAP has MRSA activity in vitro, our ﬁndings of the
innate immune-boosting effects of nafcillin in vivo (6, 7) plus the fact that nafcillin can
be given up to 12 g/day as opposed to only 1.8 g CPT raises the possibility that
potentiation of DAP activity may be achieved in combination with a number of
antistaphylococcal ␤-lactams and not exclusively with CPT. A larger study (CAMERA-2)
is currently examining the use of ﬂucloxacillin to VAN or DAP (29).
The cost effectiveness of early combination therapy in MRSA bacteremia may be
further increased by risk stratiﬁcation to preferentially allocate more cumbersome and
expensive therapy to those in whom beneﬁt would be greatest. This study employed
a post hoc assessment of IL-10 serum concentrations from study participants on the day
of initial blood culture and frozen upon patient enrollment. The samples were shipped
to ARUP laboratories, and analyzed in a blind manner through a low-sensitivity assay
that is readily available to all clinicians. This assay quantitates concentrations of IL-10 of
ⱖ5 pg/ml, which approximates the previously published cutoff of 7.8 pg/ml determined by the ultrasensitive assay. As in previous studies, an elevated IL-10 was
predictive of patient mortality in this study. A strong trend toward increased survival
was seen in patients with MRSA bacteremia with IL-10 of ⬎ 5 pg/ml that received
combination therapy compared with those that received monotherapy. There were not
aac.asm.org 6
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sufﬁcient numbers of patients with IL-10 of ⬍5 pg/ml in this study to draw meaningful
conclusions in this subgroup.
This exploratory study has some very important limitations largely centered around
its very small size and resulting random variability between the 2 groups. For example,
randomization of 40 patients resulted in a 17 versus 23 in the treatment group sizes. A
disproportionate number of cancer patients were randomized to the control monotherapy group, including 2 of them with stage IV lung cancer at the time of MRSA
bacteremia onset, which may have adversely affected their outcomes. These patients
with terminal cancer presented to the hospital and died with MRSA bacteremia as
their main diagnosis, but readers may question whether the short-term in-hospital
mortality could have been prevented with more aggressive antimicrobial therapy.
These 2 patients had high-risk endovascular infections. Despite the small study size,
all evaluated patients were enrolled, reﬂecting a “real-world” intent to treat a
patient population, rather than a “cherry-picked” population wrought with exclusionary criteria. Lastly, we acknowledge that evaluating CPT monotherapy versus
vancomycin in a similar prospective nature would be valuable to compare against
our ﬁndings.
With the minimization of patient harm in mind, the moral dilemma posed by the
disproportionate number of deaths in the standard group resulted in the early termination of this study, diminishing its statistical power and its scientiﬁc rigor, rendering
it a pilot hypothesis generating study. Although this study was prospective and
randomized, the open-label nature allowed the investigators full knowledge of the
treatments administered and patient outcomes. This openly available information
led to an early loss of equipoise due to serious concern for patient safety when a
disproportionate number of deaths were occurring in the monotherapy arm.
In summary, this exploratory study showed with a very small number of patients
that initial therapy with DAP ⫹CPT may be associated with reduced in-hospital mortality compared with the treatment standards of VAN or DAP monotherapy in patients
with MRSA bacteremia. The survival beneﬁt, if any, may be limited to patients with
high-risk endovascular sources and those with IL-10 of ⬎5 pg/ml on the day of ﬁrst
positive blood culture. Given what is potentially at stake in this pre-eminent nosocomial infection with unacceptably high treatment failure rates, we strongly encourage a larger prospective study conducted in a blind manner to determine (i) the
role of combination therapy, particularly with a ␤-lactam, in improving MRSA
bacteremia outcomes; and (ii) employing biomarkers, such as IL-10, as potential risk
stratiﬁcation tools for allocating combination therapy to those at high risk.
MATERIALS AND METHODS
Study design. Patients were randomized by computer assignment to their treatments in a prospective open-label manner. The original research protocol was registered on Clinicaltrials.gov on October 21,
2015 (registration no. NCT02660346) and subsequently reviewed, modiﬁed, and approved by the internal
review boards of participating hospitals. Notable modiﬁcations were adjustment of mortality to the
primary endpoint and the measurement of IL-10 at a reference lab rather than in our laboratory by a
high-sensitivity research-grade enzyme-linked immunosorbent assay (ELISA). Patients were enrolled at
Sharp Memorial Hospital (San Diego, CA) and Sharp Grossmont Hospital (La Mesa, CA) starting February
15, 2016, and at Henry Ford Hospital (Detroit, MI) on December 1, 2016. All participants provided written
informed consent.
Study population. Adult patients (age, ⱖ18 years) with MRSA bacteremia were identiﬁed in the
clinical microbiology laboratory by the Nanosphere Verigene Gram-positive blood culture assay (Luminex, Madison, WI). The infectious disease pharmacists and/or clinical investigational pharmacist were
notiﬁed by the local laboratory to activate infectious disease consultation and enrollment procedures. All
patients received an infectious disease consultation at the time of enrollment. Patients were excluded if
they had arrived on transfer from another facility, had ⬎72 h of pre-enrollment antibiotics, had
polymicrobial bacteremia, or who were deemed to be terminally ill with comfort-only measures at the
time of possible enrollment. All patients who were moribund (anticipated to die within 72 h of
enrollment despite full therapy) were also excluded.
Treatments. Study participants were randomized at ⱕ72 h of initial blood culture. The study group
received a combination of 6 to 8 mg/kg/day DAP plus 600 mg i.v. CPT q8h (adjusted per renal function).
The control group received monotherapy with VAN (dosed by the clinical pharmacy service to achieve
serum trough concentrations of 15 to 20 mg/liter) or 6 to 8 mg/kg/day DAP (adjusted for renal function).
Blood cultures were obtained every 24 h until clearance, with a requirement of 2 consecutive days of
May 2019 Volume 63 Issue 5 e02483-18
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negative cultures. Patients remained on the study regimen to which they were randomized for ⬎4 days,
but total duration of treatment was determined by the treating physician. At any point after 4 days (e.g.,
upon hospital discharge), the treating clinician had the option to select alternative antimicrobial therapy
and duration appropriate for the disease state and disposition of the patient. If the patient was
bacteremic for ⱖ5 days or deemed to be failing clinically on the regimen selected by the randomization
process and a source control treatment option was not evident, the treating clinician had the option to
resort to an alternative salvage regimen.
Clinical data extraction and analysis. At the time of enrollment, the following characteristics were
recorded or calculated: patient age, weight, relevant comorbidities, location at bacteremia onset (community versus health care-associated), admission ward (intensive-care unit [ICU] or non-ICU), Charlson
comorbidity index (https://www.mdcalc.com/charlson-comorbidity-index-cci; 30, 31), Pitt bacteremia
score (32), and renal function (including chronic renal insufﬁciency, end-stage renal disease requiring
dialysis, acute kidney injury; serum creatinine at time of ﬁrst positive blood culture used to calculate CrCl
via the Cockcroft-Gault method) (30). Subsequent data captured included CPT, DAP, and VAN MICs
reported by the clinical microbiology laboratory (MicroScan automated broth microdilution; Beckman
Coulter, Inc., Brea, CA), and the source of bacteremia was deﬁned by the clinical work-up. Bacteremia was
categorized into one of three risk categories based on prior literature: (i) primary endovascular bacteremia (e.g., proven or suspected endocarditis, presence of a retained intracardiac device such as left
ventricular device or pacemaker, mycotic vessel, infected hemodialysis ﬁstula or graft); (ii) secondary
bacteremia from a primary tissue focus of infection (skin, bone/joint, pulmonary, or urine); or (iii) venous
catheter-associated (33). A patient with bacteremia of ⬎48-h duration on antibiotics without an
identiﬁable focus was categorized as high-risk endovascular source/endocarditis, and treatment duration
was established on this premise.
Outcomes. Primary outcomes examined were duration of bacteremia and in-hospital mortality.
Secondary outcomes were later (60 and 90 day) mortality and length of hospital stay.
Serum interleukin-10 measurement. At the time of patient enrollment and randomization, serum
collected on the day of the ﬁrst positive blood culture as part of routine medical management was
obtained from the clinical laboratory and frozen at ⫺20°C in 0.5-ml aliquots. Samples were sent to ARUP
reference laboratories (Salt Lake City, UT) for a post hoc measurement in a blind manner of IL-10
concentration via a quantitative multiplex bead assay (ltd.aruplab.com/Tests/Pub/0051534), and results
were reported back to the principal investigator (PI; author G.S.) for analysis. This assay quantitates and
reports IL-10 concentrations of ⱖ5 pg/ml, a value close to our previous cutoff of 7.8 pg/ml deemed to
predict mortality (15). The ⱖ5-pg/ml cutoff was applied for mortality assessment in this study.
Statistical analysis. The planned enrollment sample size was 50 patients. However, after 40 patients
were enrolled, the investigators perceived a mortality risk to the monotherapy patients, leading to an
ethical obligation to halt the study on July 14, 2017. The data were then compiled and reviewed
independently with two physician experts from other institutions who were not involved with study
design or execution, including enrollment, and were not involved in the ﬁnal outcome evaluation of the
study. These physician experts provided the investigators with an unbiased perspective in the clinical
management of these patients. These reviews occurred separately with each of the experts, with the
question of whether the study ethically could continue by these investigators given the outcomes
observed. Both experts independently agreed to halt the study due to the loss of equipoise with
available data but that a larger and more comprehensive study conducted in a blind manner, including
an independent data monitoring safety board, would be needed for a deﬁnitive answer in changing
treatment standards. The study was ofﬁcially terminated and the results reported herein.
All analyses were performed on the intent to treat the population. Statistical differences in mortality
at the various time points and other categorical or ordinal variables were calculated using a 2-tailed
Fisher’s exact test, and differences in continuous variables were calculated using the Mann-Whitney U
test. Survival curves were generated with the Kaplan-Meier estimate method, and the log-rank test was
used to compare standard therapy versus combination therapy survival at 60 days. For these comparisons, a P value of ⬍0.05 was considered statistically signiﬁcant.
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